Short Interest in MetaVia Inc. (NASDAQ:MTVA) Decreases By 53.4%

MetaVia Inc. (NASDAQ:MTVA) saw a large decrease in short interest in July. As of July 31st, there was short interest totaling 160,464 shares, a decrease of 53.4% from the July 15th total of 344,566 shares. Approximately 3.1% of the company’s stock are short sold. Based on an average daily volume of 100,346 shares, the days-to-cover ratio is currently 1.6 days.

MetaVia Price Performance

Shares of NASDAQ:MTVA traded up $0.03 during midday trading on Friday, hitting $1.49. 69,155 shares of the company’s stock were exchanged, compared to its average volume of 91,237. MetaVia has a 12 month low of $0.97 and a 12 month high of $19.03. The company has a market cap of $7.69 million, a PE ratio of -0.46 and a beta of 0.95. The stock has a 50 day moving average price of $1.60 and a 200-day moving average price of $1.69.

MetaVia (NASDAQ:MTVA) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.08). On average, analysts anticipate that MetaVia will post -2.79 EPS for the current fiscal year.

Institutional Investors Weigh In On MetaVia

A hedge fund recently bought a new stake in MetaVia stock. Virtu Financial LLC bought a new stake in MetaVia Inc. (NASDAQ:MTVA) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned approximately 0.14% of MetaVia as of its most recent SEC filing. 1.37% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

MTVA has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MetaVia in a research report on Tuesday, July 21st. HC Wainwright restated a “buy” rating on shares of MetaVia in a report on Friday, July 10th. Finally, Wall Street Zen raised MetaVia to a “sell” rating in a research report on Saturday, June 20th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $20.00.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.